High-Output Heart Failure and Dialysis Access
AV fistulas and AV grafts are essential for hemodialysis, but they create low-resistance vascular circuits that can increase venous return and cardiac output demand — and, in some patients, contribute to cardiac remodeling, pulmonary hypertension, and high-output heart failure.
An AV fistula or AV graft connects an artery directly to a vein, providing the reliable high flow needed for dialysis. The same anatomy that makes hemodialysis possible, however, can also impose continuous extra work on the heart. This page explains how dialysis access affects cardiac output, what symptoms patients and clinicians may notice, and how flow-control dialysis access is being discussed as a more cardiac-conscious approach.
How dialysis access affects the heart
In a healthy circulation, blood pumped from the heart passes through a high-resistance capillary bed before returning to the venous side. A surgically created AV fistula or AV graft bypasses that resistance, allowing blood to travel directly from artery to vein. The result is a sustained increase in venous return and in the volume of blood the heart must pump every minute.
This is not a transient effect during a dialysis session. The shunt is present 24 hours a day, every day, for as long as the access is in place. The cumulative cardiac burden is what distinguishes the hemodynamics of long-term dialysis access from many other clinical conditions.
High-flow AV access and high-output heart failure
High-output heart failure is a clinical state in which the heart pumps an unusually large volume of blood per minute and yet remains unable to meet the body's needs. High-flow dialysis access — high-flow AV fistulas and high-flow AV grafts — can contribute to this state by layering a continuous, non-physiologic flow load on top of any underlying cardiovascular disease.
Cardiac remodeling and pulmonary hypertension are commonly discussed in this context. Both can develop in response to sustained increases in cardiac output demand, and both can precede or accompany high-output heart failure in susceptible patients. The relationship is not deterministic — many patients tolerate dialysis access without progressing to heart failure — but the field increasingly recognizes the access circuit itself as a relevant cardiac variable.
Symptoms and clinical concerns
Several symptoms are sometimes associated with high-flow dialysis access and the cardiac burden it can create, including:
- Shortness of breath, especially with exertion or when lying flat
- Fatigue beyond what is typical for the patient
- Exercise intolerance or reduced functional capacity
- Signs of pulmonary hypertension on imaging or right-heart catheterization
- Heart-failure symptoms such as swelling in the legs or worsening overall function
These symptoms have many possible causes, including those unrelated to dialysis access, and are not by themselves diagnostic of high-output heart failure. Any new or worsening symptoms in a hemodialysis access patient warrant evaluation by a physician familiar with the patient's history. This page is informational and is not medical advice.
Why access flow matters
The volume of blood moving through an AV fistula or AV graft — the access flow — is the most direct lever on the cardiac burden created by the access. Historically, access flow has been discussed using fixed thresholds such as 1.5 to 2.0 L/min, but recent discussion in the field, including at the Vascular Access Society of the Americas (VASA), has emphasized that clinically meaningful cardiac changes may occur at considerably lower access-flow levels. The more useful frame is the physiologic effect on the patient, not the access-flow number alone.
For more on the broader category, see high-flow dialysis access.
Access flow reduction and current clinical approaches
When high-flow access is identified, clinicians may consider access flow reduction — a strategy that lowers the volume of blood moving through the access while preserving its function for dialysis. Several technical approaches exist, including surgical banding, balloon-assisted maturation reversal, and other revision procedures. These approaches are typically pursued after symptoms or complications have appeared.
Reactive access flow reduction can be effective but has limitations: it requires a separate intervention, it intervenes after some degree of cardiac burden has accumulated, and it does not change the design assumption that the access should default to maximal flow. The field has begun to consider whether controlled flow should be a property of the access itself.
Flow-control dialysis access
Flow-control dialysis access is an emerging category designed around two simultaneous goals: adequate dialysis and patient cardiac tolerance. Rather than maximizing access flow and intervening later, flow-control approaches incorporate controlled access flow into the design of the graft or stent from the start. The category includes flow-control grafts and flow-control stents.
The framing matters because it changes what the access is optimized for. In a flow-control framework, the question is not "how much flow can we get?" but "how much flow does the patient need for dialysis, and how much can the heart tolerate over time?" For more on the category, see flow-control dialysis access.
VascX and cardiac-conscious access design
VascX is a medical device company developing patented elastic flow-control implants for dialysis access. The VascX platform includes elastic flow-control grafts and elastic flow-control stents intended to reduce excessive access flow while preserving dialysis adequacy. The elastic design is intended to accommodate standard access interventions, including thrombectomy, and return to its calibrated profile afterward.
VascX products are investigational. The company does not claim that its devices are proven to treat or prevent cardiac remodeling, pulmonary hypertension, high-output heart failure, hospitalization, or mortality. The platform is designed to address the underlying physiology — access flow — that the field increasingly views as relevant to cardiac outcomes in dialysis patients.